Technologies
PDF


WARF: P07490US02

Small Molecule Therapeutics to Inhibit HPV Infection


INVENTORS -

Paul Ahlquist, Paul Lambert, Dohun Pyeon, Shane Pearce

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing methods and therapeutics to inhibit double-stranded DNA virus infection, particularly HPV infection.
OVERVIEWHuman papillomaviruses (HPVs) are the most common sexually transmitted pathogens. These small DNA viruses are associated with almost all cervical cancers and 20 to 30 percent of head and neck cancers.

Cervical cancer is the second most common cancer in women worldwide. It is a major cause of morbidity and mortality. Head and neck cancer is the fourth most frequent cancer worldwide and the sixth most common cancer in the U.S. The survival rate is less than 50 percent, and that statistic has not improved in decades.

Vaccines against HPV have been developed, but their long-term effects and ability to prevent cervical cancer are unknown. Even if current vaccines are 100 percent effective, they only will prevent cancers arising from infection by two of the high risk HPV genotypes, HPV16 and HPV18. Because the vaccines are not expected to show an impact on the frequency of cervical cancer until 2040 or later, new therapies to effectively treat or prevent HPV infections could be of great value to clinicians and their patients.
THE INVENTIONUW–Madison researchers have developed new methods and compositions for inhibiting HPV infection. These inhibitors could complement and/or replace current vaccine treatment.

The researchers found that cell cycle progression through mitosis is critical for HPV infection. Host cells must pass through early prophase before transcription of HPV-encapsidated genes. Exposing a papillomavirus to an effective amount of a G1, S, G2 or early M phase cell cycle inhibitor or administering one of the inhibitors to a susceptible tissue or cell therefore provides a new approach to the prevention and treatment of HPV infection.
APPLICATIONS
  • Prevention or treatment of HPV infection
  • Inhibition of other papovaviruses, double-stranded DNA viruses or retroviruses
KEY BENEFITS
  • Provides a new approach for the development of preventive and therapeutic strategies against HPV infection
  • Increases understanding of HPV by defining a major condition for cell susceptibility to HPV infection
  • Could be incorporated into a variety of products, including spermicides, lubricants, suppositories, ointments or tampons
ADDITIONAL INFORMATION
For More Information About the Inventors
Contact Information
For current licensing status, please contact Jennifer Gottwald at jennifer@warf.org or 608-960-9854.
The WARF Advantage

WARF: A Leader in Technology Transfer Since 1925
Since its founding as a private, nonprofit affiliate of the University of Wisconsin–Madison, WARF has provided patent and licensing services to UW–Madison and worked with commercial partners to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.

The University of Wisconsin and WARF –
A Single Location to Accelerate Translational Development of New Drugs

UW–Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities for research in the country, UW–Madison offers state-of-the-art facilities unmatched by most public universities.

These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW–Madison with a complete translational research facility; and the innovative, interdisciplinary Wisconsin Institutes for Discovery, home to the private, nonprofit Morgridge Institute for Research and its public twin, WID, part of the university's graduate school. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.